Actionable news
All posts from Actionable news
Actionable news in RVNC: REVANCE THERAPEUTICS Inc,

Revance: Key Efficacy, Safety And Duration Data Belmont 24-Week Interim Results

The following excerpt is from the company's SEC filing.

100% Response Rates For All RT002 Doses Placebo N=35 BOTOX N=34 RT002 20U N=39 RT002 40U N=41 RT002 60U N=42 ≥ 1 pt 3% 95% 100% 100% 100% ≥ 2 pt 0% 76% 74% 85% 95%* None or Mild 0% 93% 97% 97% 98% Confidential and Proprietary * Statistically significant vs. BOTOX Cosmetic. Study not powered for statistical significance at Week 4 Week 4 Investigator Efficacy Analyses (PP) *BOTOX® (VISTABEL® in Canada) are registered trademarks of Allergan, Inc.

Summary of Safety (Safety Population) All five groups exhibited an excellent overall safety profile in interim data No serious adverse events Adverse events were pr edominantly localized, transient and mild in severity and typically injection related (erythema and pain) Most common adverse events by subject RT002 dosed at 20U and 40U exhibited NO EYELID PTOSIS BOTOX had 1.9% ptosis (N=1) RT002 at 60U had 5.7% ptosis (N=3) Confidential and Proprietary Placebo N=54 BOTOX N=54 RT002 20U N=53 RT002 40U N=53 RT002 60U N=54 Headache 3 10 6 4 3 Erythema 4 5 3 4 3 *BOTOX® (VISTABEL® in Canada) are registered trademarks of Allergan, Inc.

Duration of Effect Separates RT002 from BOTOX...